Bonnevie-Nielsen V, Heron I, Monath T P, Calisher C H
Department of Medical Microbiology, Odense University, Denmark.
Clin Diagn Lab Immunol. 1995 May;2(3):302-6. doi: 10.1128/cdli.2.3.302-306.1995.
Primary and secondary immunizations with live, attenuated yellow fever virus vaccine (17D strain) were performed in order to study the course of appearance of virus-neutralizing antibodies and immunoglobulin M (IgM) and IgG antibodies directed against the virus and the interferon-dependent enzyme 2',5'-oligoadenylate synthetase (2',5'AS) activity, determined in homogenates of peripheral B and T lymphocytes. From cellular ATP, this enzyme generates 2',5'-oligoadenylates which mediate degradation of viral mRNA by stimulation of a latent RNase. By day 4 after the first immunization, the earliest and highest 2',5'AS activity was present in the T-lymphocyte fraction. By day 7, the enzyme activity was highest in the B-lymphocyte fraction. Virus-neutralizing antibodies appeared on day 7, and IgM antibodies were present on day 12. After the second immunization, performed 2 years +/- 2 months later, the only significant increase in 2',5'AS activity was observed in the T-lymphocyte fraction. Virus-neutralizing antibodies were present from day 1, whereas no IgM antibodies were detected. By day 12, 80% of the vaccines were IgG positive. In the primary and secondary (memory) immune responses, 2',5'AS activity is expressed in the T-lymphocyte fraction prior to the appearance of antibodies directed against the virus and may serve as an early and sensitive marker of an ongoing virus infection which is otherwise difficult to detect. No change in conventional laboratory analysis parameters, such as in differential blood cell counts or total IgA, IgG, and IgM, disclosed the immune activity in either the primary or the secondary immunization.
为了研究病毒中和抗体、针对该病毒的免疫球蛋白M(IgM)和IgG抗体以及干扰素依赖性酶2',5'-寡腺苷酸合成酶(2',5'AS)活性的出现过程,对减毒活黄热病毒疫苗(17D株)进行了初次和二次免疫接种,这些指标是在外周B淋巴细胞和T淋巴细胞匀浆中测定的。该酶从细胞ATP生成2',5'-寡腺苷酸,通过刺激潜伏的核糖核酸酶介导病毒mRNA的降解。首次免疫接种后第4天,T淋巴细胞部分出现最早且最高的2',5'AS活性。到第7天,该酶活性在B淋巴细胞部分最高。病毒中和抗体在第7天出现,IgM抗体在第12天出现。在2年±2个月后进行二次免疫接种后,仅在T淋巴细胞部分观察到2',5'AS活性有显著增加。病毒中和抗体从第1天就存在,而未检测到IgM抗体。到第12天,80%的疫苗接种者IgG呈阳性。在初次和二次(记忆)免疫反应中,2',5'AS活性在针对病毒的抗体出现之前在T淋巴细胞部分表达,并且可能作为正在进行的病毒感染的早期敏感标志物,否则这种感染很难检测到。常规实验室分析参数,如血细胞分类计数或总IgA、IgG和IgM,在初次或二次免疫接种中均未显示出免疫活性变化。